News Sentiment

MRKR sentiment intelligence

Marker Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.51 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

73/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+2.7% over one week, +9.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Wainwright reiterates Buy on Marker Therapeutics stock, $10 target By Investing.com

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 73/100 classification
One-week reaction 2.7% Price confirming higher
Trend fit Trend inactive 9.4% over four weeks
Fair value -45.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 29
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Market source 7
TradingKey 7
Stock Titan 3
simplywall.st 3
Investing.com Canada 2
DonanımHaber 2
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Earnings 17
Market update 17
Analyst action 6
Balance sheet 5
Guidance 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
Investing.com Canada Direct company coverage

Wainwright reiterates Buy on Marker Therapeutics stock, $10 target By Investing.com

H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Marker Therapeutics (NASDAQ:MRKR) after a fireside chat with the company's management. The conversation focused on their lead cell therapy program, MT-601, developed for lymphoma and pancreatic cancer, whic

Tone
Positive 71/100
Event
Analyst action
Published
10 Jul 2026 12:09
Source
Investing.com Canada
Simply Wall Street Direct company coverage

Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Profit Outlook

Marker Therapeutics (NASDAQ:MRKR) is projected by analysts to achieve profitability around 2028, after incurring a final loss in 2027. This breakeven projection relies on a highly buoyant average annual growth rate of 69%. The company currently has no debt, which reduces investme

Tone
Positive 70/100
Event
Guidance
Published
02 Jul 2026 10:39
Source
Simply Wall Street
TradingView Direct company coverage

Price to book forward of Marker Therapeutics, Inc. – NASDAQ:MRKR

This article provides a financial metric for Marker Therapeutics, Inc. (NASDAQ: MRKR), specifically its "Price to book forward." The content is primarily a placeholder or incomplete financial data from TradingView, indicating that the market for MRKR was closed with no trades at

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 17:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Marker Therapeutics, Inc. – NASDAQ:MRKR

This article provides financial information for Marker Therapeutics, Inc. (NASDAQ:MRKR), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of publication, with no trades reported. The content appears to be a financia

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 22:40
Source
TradingView
TradingView Direct company coverage

Marker Therapeutics, Inc. Actuals & Estimates (NASDAQ:MRKR)

This article provides an overview of Marker Therapeutics, Inc. (NASDAQ: MRKR) financials, stock performance, and analyst forecasts. It covers key metrics such as current stock price, historical highs and lows, market capitalization, earnings, revenue, and EBITDA. The company's ne

Tone
Negative 42/100
Event
Earnings
Published
26 Jun 2026 06:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Marker Therapeutics, Inc. – NASDAQ:MRKR

This article provides financial data for Marker Therapeutics, Inc. (NASDAQ: MRKR), specifically focusing on its forward price-to-sales ratio. The content appears to be a stub or an incomplete financial data page from TradingView.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 02:40
Source
TradingView
TradingView Direct company coverage

MRKR Forecast — Price Target — Prediction for 2027

This article provides a forecast for Marker Therapeutics, Inc. (MRKR) stock, including analyst price targets and predictions for 2027. It details recent stock performance, financial metrics like revenue and earnings per share, and other company information such as market capitali

Tone
Positive 66/100
Event
Earnings
Published
25 Jun 2026 06:11
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Marker Therapeutics, Inc. – NASDAQ:MRKR

This article provides the enterprise value to EBIT forward for Marker Therapeutics, Inc. (NASDAQ: MRKR). It is presented as part of financial data available on TradingView, which offers various market tools and information for investors. The content primarily focuses on presentin

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 18:10
Source
TradingView
TradingKey Direct company coverage

Marker Therapeutics Inc (MRKR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Marker Therapeutics Inc (MRKR), highlighting its current price momentum score of 5.39 within the Biotechnology & Medical Research industry. It identifies the stock trading between a resistance level of $1.50 and a support level of $1.

Tone
Negative 19/100
Event
Market update
Published
18 Jun 2026 22:40
Source
TradingKey
TradingKey Direct company coverage

Marker Therapeutics Inc (MRKR) Valuation: PE, PB & Fair Value Analysis

Marker Therapeutics Inc (MRKR) currently has a valuation score of 8.40, placing it 137th out of 389 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -2.38, showing a significant percentage difference from both its recent high and low P

Tone
Negative 40/100
Event
Market update
Published
18 Jun 2026 21:41
Source
TradingKey
TradingKey Direct company coverage

Marker Therapeutics Inc (MRKR) Institutional Confidence

Marker Therapeutics Inc (MRKR) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 26.04%, marking a 17.09% increase quarter-over-quarter. James Simons i

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 06:39
Source
TradingKey
TradingKey Direct company coverage

Marker Therapeutics Inc (MRKR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Marker Therapeutics Inc (MRKR) currently has an earnings forecast score of 8.00, ranking 163rd in its industry. Analysts have set an average price target of $9.00 for MRKR, with a "Buy" rating from most analysts. The company's expected revenue for the next quarter is $682.00K, an

Tone
Positive 75/100
Event
Earnings
Published
18 Jun 2026 01:10
Source
TradingKey
TradingKey Direct company coverage

Marker Therapeutics Inc (MRKR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey focuses on the revenue breakdown of Marker Therapeutics Inc (MRKR). It states that relevant data regarding the company's revenue by business segments and by region has not yet been disclosed. The article provides a stock quote for MRKR, showing a slig

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 22:10
Source
TradingKey
TradingKey Direct company coverage

Marker Therapeutics Inc (MRKR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of the dividend and stock split history for Marker Therapeutics Inc (MRKR). It notes that the company has not distributed any dividends over the past five years. The page also details several 10-to-1 merger-related stock splits that occurred on J

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 21:10
Source
TradingKey
Finviz Direct company coverage

MRKR - Marker Therapeutics Inc Stock Price and Quote

This article provides a comprehensive overview of Marker Therapeutics Inc (MRKR) stock, including its latest price, financial data, performance metrics, and recent news. It details key financial figures, stock performance comparisons, analyst ratings, and a chronology of signific

Tone
Positive 62/100
Event
Analyst action
Published
30 May 2026 02:39
Source
Finviz
Investing.com Canada Direct company coverage

H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com

H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Marker Therapeutics (NASDAQ: MRKR) after the company reported its first-quarter 2026 financial results. The company holds more cash than debt, and its liquid assets exceed short-term obligations, indicating

Tone
Positive 74/100
Event
Analyst action
Published
24 May 2026 13:38
Source
Investing.com Canada
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Merck & Company (MRK) and Cullinan Management (CGEM)

This article provides analyst insights on three healthcare companies: Marker Therapeutics (MRKR), Merck & Company (MRK), and Cullinan Management (CGEM). Analysts reiterated "Buy" ratings for Marker Therapeutics and Cullinan Management, with significant upside potential, while Mer

Tone
Positive 90/100
Event
Analyst action
Published
22 May 2026 16:09
Source
The Globe and Mail
Investing.com Direct company coverage

H.C. Wainwright reiterates Marker Therapeutics stock rating at buy

H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Marker Therapeutics (NASDAQ:MRKR) following its first-quarter 2026 financial results. The company reported $1.4 million in operating cash use, ending the quarter with $15.6 million in cash, cash equivalents

Tone
Positive 65/100
Event
Earnings
Published
20 May 2026 12:09
Source
Investing.com
TradingView Direct company coverage

MRKR: Net loss improved to $3.2M in Q1 2026, with cash funding expected through Q1 2027

Marker Therapeutics (MRKR) reported an improved net loss of $3.2 million in Q1 2026, attributed to lower expenses and increased grant income. The company anticipates its $15.6 million cash reserves will fund operations until Q1 2027. However, the report highlights substantial dou

Tone
Positive 59/100
Event
Balance sheet
Published
16 May 2026 09:43
Source
TradingView
TradingView Direct company coverage

Marker Therapeutics, Inc. Q1 2026: Net loss $(3.18M), Diluted EPS $(0.16) — 10-Q Summary

Marker Therapeutics, Inc. reported a net loss of $(3.18M) in Q1 2026, an improvement from a $(4.45M) loss in Q1 2025, with diluted EPS at $(0.16). This improvement was partly due to increased grant income and progress in clinical trials, particularly with their APOLLO study and a

Tone
Positive 66/100
Event
Earnings
Published
15 May 2026 21:10
Source
TradingView
Stock Titan Direct company coverage

Marker Therapeutics (MRKR) narrows Q1 2026 loss but warns on going concern

Marker Therapeutics (MRKR) reported a narrowed net loss of $3.2 million in Q1 2026, down from $4.4 million a year ago, attributing the improvement to reduced operating expenses and increased grant income. However, the pre-revenue biotech firm currently has $15.6 million in cash,

Tone
Negative 36/100
Event
Balance sheet
Published
15 May 2026 21:10
Source
Stock Titan